SELLAS Life Sciences Group, Inc. (SLS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.86+1.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SLS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
SLS — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition. On August 11, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Why it matters: SELLAS reported $138.3 million in cash. Changes could impact their ability to fund ongoing trials and operations.
Worry ifCash position stays stable or grows because of successful fundraising.
Less concerning ifCash position drops a lot due to higher expenses than expected.
Why it matters: Higher expenses may show problems in managing cash, which can affect future funding.
Worry ifOperating expenses go up a lot, over $10 million, in the next quarter.
Less concerning ifOperating expenses stay the same or drop below $10 million in the next quarter.
Why it matters: The 80th event will trigger a database lock and data review. This is key for the final analysis and potential FDA submission.
Supportive ifAnnouncement of the 80th event occurring in the Phase 3 REGAL trial.
Worry ifNo announcement of the 80th event by the end of Q4 2026.
Why it matters: Having strong cash is important for funding trials and daily operations. Changes could affect stability.
Watch forThe company has more than $138 million in cash and cash equivalents after Q2 2026.
Also watch forCash and cash equivalents drop below $130 million. This shows there may be cash burn problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$437 on $10,000 · ±4.4% | How much price usually moves either way. |
| Bad day | $859 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,624 loss on $10,000 · 36.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Topline data from this trial is expected in Q4 2026. Positive results could support further development and investment.
Supportive ifTopline data shows positive results from the Phase 2 trial of SLS009.
Worry ifThe main data shows no big safety or effectiveness problems.
Why it matters: Cash position impacts the ability to fund ongoing clinical trials. A strong position supports growth.
Supportive ifThe company reports a big increase in cash due to warrant exercises.
Worry ifCash position goes down or does not get better after warrant exercises.
Why it matters: Progress in clinical trial enrollment is key for future data releases and growth.
Supportive ifEnrollment numbers go up a lot. This shows faster progress to topline data.
Worry ifEnrollment numbers stay the same or drop. This delays topline data release.
Why it matters: Continued high cash burn could signal financial strain. Monitoring this will help assess the company's financial health.
Worry ifCash burn is much lower than in past quarters.
Less concerning ifCash burn is still high or goes up. This shows financial problems continue.
Why it matters: Managing cash burn is key. It helps fund clinical trials and operations.
Worry ifOperating expenses go down a lot. This shows better cost management.
Less concerning ifOperating expenses go up or stay high. This shows ongoing cash burn problems.
Why it matters: R&D costs went up a lot in Q2 2026. More increases may mean financial issues.
Worry ifR&D expenses increase beyond $6.3 million in future quarters.
Less concerning ifR&D costs stay the same or go down, showing better cost control.